{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:27:34Z","timestamp":1793039254847,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier","isbn-type":[{"value":"9780128177402","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2019.02.003","type":"book-chapter","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T14:33:46Z","timestamp":1553524426000},"page":"21-39","source":"Crossref","is-referenced-by-count":94,"title":["Low molecular weight heparins and their clinical applications"],"prefix":"10.1016","author":[{"given":"Cui","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/bs.pmbts.2019.02.003_bb0010","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1007\/s00216-011-5367-7","article-title":"Structural characterization of heparins from different commercial sources","volume":"401","author":"Zhang","year":"2011","journal-title":"Anal Bioanal Chem"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.003_bb0015","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/brv.12034","article-title":"Glycosaminoglycans in infectious disease","volume":"88","author":"Kamhi","year":"2013","journal-title":"Biol Rev Camb Philos Soc"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0020","first-page":"89","article-title":"Low molecular weight heparin: a critical analysis of clinical trials","volume":"46","author":"Green","year":"1994","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2141.1995.tb03373.x","article-title":"Low molecular weight heparin(s)","volume":"90","author":"Barrowcliffe","year":"1995","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.003_bb0030","first-page":"362","article-title":"Current use of low molecular weight heparins","volume":"9","author":"Donayre","year":"1996","journal-title":"Semin Vasc Surg"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00007611-199801000-00001","article-title":"Low-molecular-weight heparins in clinical practice","volume":"91","author":"Hunt","year":"1998","journal-title":"South Med J"},{"issue":"5B","key":"10.1016\/bs.pmbts.2019.02.003_bb0040","doi-asserted-by":"crossref","first-page":"3L","DOI":"10.1016\/S0002-9149(98)00105-2","article-title":"Low-molecular-weight heparins: pharmacologic profile and product differentiation","volume":"82","author":"Fareed","year":"1998","journal-title":"Am J Cardiol"},{"issue":"suppl 3","key":"10.1016\/bs.pmbts.2019.02.003_bb0045","first-page":"5","article-title":"Production and chemical processing of low molecular weight heparins","volume":"25","author":"Linhardt","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"20","key":"10.1016\/bs.pmbts.2019.02.003_bb0050","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.003_bb0055","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FJC.0b013e3181a59abc","article-title":"Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes","volume":"53","author":"Nicolau","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/A:1011969005756","article-title":"Applying scientific criteria to therapeutic interchange: a balanced analysis of low-molecular-weight heparins","volume":"11","author":"Merli","year":"2001","journal-title":"J Thromb Thrombolysis"},{"issue":"suppl 3","key":"10.1016\/bs.pmbts.2019.02.003_bb0065","first-page":"33","article-title":"Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins","volume":"18","author":"Fareed","year":"1988","journal-title":"Haemostasis"},{"issue":"suppl E","key":"10.1016\/bs.pmbts.2019.02.003_bb0070","first-page":"28E","article-title":"Low molecular weight heparins: are they different?","volume":"14","author":"Fareed","year":"1998","journal-title":"Can J Cardiol"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2019.02.003_bb0075","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1177\/10760296990050S111","article-title":"Low molecular weight heparins: differences and similarities in approved preparations in the United States","volume":"5","author":"Bick","year":"1999","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.02.003_bb0080","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2174\/1381612043452811","article-title":"Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile","volume":"10","author":"Fareed","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"suppl 2","key":"10.1016\/bs.pmbts.2019.02.003_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/1158583-S0-000000000-00000","article-title":"Overview of venous thromboembolism","volume":"70","author":"Abad Rico","year":"2010","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3466.2002.tb00087.x","article-title":"The low molecular weight heparin, tinzaparin, in thrombosis and beyond","volume":"20","author":"Mousa","year":"2002","journal-title":"Cardiovasc Drug Rev"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2019.02.003_bb0095","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1538-7836.2011.04334.x","article-title":"How to prevent, treat, and overcome current clinical challenges of VTE","volume":"9","author":"Van Es","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0100","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/TA.0000000000000087","article-title":"Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients","volume":"76","author":"Droege","year":"2014","journal-title":"J Trauma Acute Care Surg"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0105","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1538-7836.2012.04669.x","article-title":"A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis","volume":"10","author":"Rathbun","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.02.003_bb0110","first-page":"950","article-title":"Update on low molecular weight heparins at the beginning of third millennium. Focus on reviparin","volume":"15","author":"Del Bono","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.02.003_bb0115","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1517\/17425255.2013.794787","article-title":"Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies","volume":"9","author":"Donadini","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/bs.pmbts.2019.02.003_bb0120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2369-13-50","article-title":"A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis\u2014the membrane study","volume":"13","author":"Dorsch","year":"2012","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-10-10","article-title":"Comparison of 3,000 and 5,000 IU aXa\/day certoparin in the prevention of deep-vein thrombosis after total hip replacement","volume":"10","author":"Bramlage","year":"2012","journal-title":"Thromb J"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0130","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1097\/PCC.0000000000000049","article-title":"IV enoxaparin in pediatric and cardiac ICU patients","volume":"15","author":"Cies","year":"2014","journal-title":"Pediatr Crit Care Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000441442","article-title":"Comparison between fondaparinux and low-molecular-weight heparin in patients with acute coronary syndrome: a meta-analysis","volume":"133","author":"Qiao","year":"2016","journal-title":"Cardiology"},{"key":"10.1016\/bs.pmbts.2019.02.003_bb0140","article-title":"Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke","volume":"4","author":"Sandercock","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0145","first-page":"807","article-title":"Heparin and low-molecular-weight heparin","volume":"99","author":"Gray","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/bs.pmbts.2019.02.003_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2431-14-27","article-title":"Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study","volume":"14","author":"Inamo","year":"2014","journal-title":"BMC Pediatr"},{"issue":"3\u20134","key":"10.1016\/bs.pmbts.2019.02.003_bb0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000356384","article-title":"Pharmacokinetics of dalteparin during haemodialysis","volume":"124","author":"Nigten","year":"2013","journal-title":"Nephron Clin Pract"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2019.02.003_bb0160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000348830","article-title":"Dalteparin dosing in high-flux haemodialysis and haemodiafiltration","volume":"122","author":"Sridharan","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"12","key":"10.1016\/bs.pmbts.2019.02.003_bb0165","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1600-0463.2010.02635.x","article-title":"Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo","volume":"118","author":"Norrby","year":"2010","journal-title":"APMIS"},{"issue":"14","key":"10.1016\/bs.pmbts.2019.02.003_bb0170","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa1014475","article-title":"Dalteparin versus unfractionated heparin in critically ill patients","volume":"364","author":"Group PIftCCCT, the A, New Zealand Intensive Care Society Clinical Trials G","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0175","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1053\/j.ajkd.2012.01.020","article-title":"Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial","volume":"60","author":"Rodger","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1517\/14656566.3.2.173","article-title":"Reviparin sodium\u2014a new low molecular weight heparin","volume":"3","author":"Breddin","year":"2002","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-2007-996079","article-title":"Biochemical and pharmacologic characteristics of reviparin, a low-molecular-mass heparin","volume":"23","author":"Jeske","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7326\/ACPJC-2005-143-1-004","article-title":"Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MI","volume":"143","author":"Berger","year":"2005","journal-title":"ACP J Club"},{"issue":"10","key":"10.1016\/bs.pmbts.2019.02.003_bb0195","first-page":"589","article-title":"Reviparin sodium clivarine: a review of its therapeutic use","volume":"102","author":"Gore","year":"2004","journal-title":"J Indian Med Assoc"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0200","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1532\/IJH97.E0408","article-title":"Thromboprophylaxis with reviparin in a patient with acquired hemophilia","volume":"81","author":"De Giorgi","year":"2005","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.003_bb0205","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/ndt\/gfh071","article-title":"Severe anaphylactic reaction in a haemodialysis patient after administration of reviparin","volume":"19","author":"Basic-Jukic","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.003_bb0210","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5301\/hipint.5000039","article-title":"Postoperative plasma D-dimer value for predicting deep venous thrombosis following hip arthroplasty with nadroparin prophylaxis","volume":"23","author":"Xu","year":"2013","journal-title":"Hip Int"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0215","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1089\/jop.2012.0012","article-title":"Subcutaneous nadroparin calcium in the treatment of recent onset retinal vein occlusion: a pilot study","volume":"28","author":"Pinna","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0220","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1076029611429123","article-title":"The influence of decreased low-molecular-weight heparin nadroparin dose on diastolic blood pressure in patients on hemodialysis","volume":"18","author":"Sain","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0225","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1078155209353465","article-title":"Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases","volume":"17","author":"Vitale","year":"2011","journal-title":"J Oncol Pharm Pract"},{"issue":"suppl 5 (pt 2)","key":"10.1016\/bs.pmbts.2019.02.003_bb0230","first-page":"603","article-title":"Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects","volume":"58","author":"Scheuch","year":"2007","journal-title":"J Physiol Pharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0235","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1076029612449899","article-title":"Prospective, non-interventional study on the real-world use of certoparin in daily practice\u2014the PROMEMBER study","volume":"19","author":"Spannagl","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0240","doi-asserted-by":"crossref","first-page":"R541","DOI":"10.1186\/cc3792","article-title":"Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study","volume":"9","author":"Jochberger","year":"2005","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0245","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1517\/13543784.8.3.315","article-title":"Pharmacologic profile of certoparin","volume":"8","author":"Jeske","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/bs.pmbts.2019.02.003_bb0250","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.carbpol.2014.01.100","article-title":"A world of low molecular weight heparins (LMWHs) enoxaparin as a promising moiety\u2014a review","volume":"106","author":"Ingle","year":"2014","journal-title":"Carbohydr Polym"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0255","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.tvjl.2014.03.032","article-title":"Enoxaparin: pharmacokinetics and treatment schedule for cats","volume":"200","author":"Mischke","year":"2014","journal-title":"Vet J"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0260","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3944\/AOTT.2014.13.0075","article-title":"Effects of enoxaparin and rivaroxaban on tissue survival in skin degloving injury: an experimental study","volume":"48","author":"Azboy","year":"2014","journal-title":"Acta Orthop Traumatol Turc"},{"key":"10.1016\/bs.pmbts.2019.02.003_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2014.03.002","article-title":"Development and evaluation of PEGylated enoxaparin: a novel approach for enhanced anti-Xa activity","volume":"54","author":"Choubey","year":"2014","journal-title":"Bioorg Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0270","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1024\/0301-1526\/a000338","article-title":"Effects of enoxaparin and dalteparin on proliferation and migration of patient-derived vascular smooth muscle cells","volume":"43","author":"Ellensen","year":"2014","journal-title":"Vasa"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.003_bb0275","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4318\/tjg.2013.0585","article-title":"Preventive effects of enoxaparin and hesperidin in cerulein-induced acute pancreatitis in rats","volume":"24","author":"Koksoy","year":"2013","journal-title":"Turk J Gastroenterol"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.003_bb0280","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.thromres.2013.10.005","article-title":"Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms","volume":"132","author":"Rojas","year":"2013","journal-title":"Thromb Res"},{"issue":"7\u20138","key":"10.1016\/bs.pmbts.2019.02.003_bb0285","first-page":"281","article-title":"Enoxaparin for the treatment of recurrent aphthous stomatitis: a pilot exploratory clinical trial","volume":"62","author":"Ghaffari","year":"2013","journal-title":"Minerva Stomatol"},{"issue":"suppl 2","key":"10.1016\/bs.pmbts.2019.02.003_bb0290","first-page":"43","article-title":"New frontiers with bemiparin: use in special populations","volume":"70","author":"Fontcuberta","year":"2010","journal-title":"Drugs"},{"issue":"suppl 2","key":"10.1016\/bs.pmbts.2019.02.003_bb0295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/1158584-S0-000000000-00000","article-title":"Clinical experience with bemiparin","volume":"70","author":"Abad Rico","year":"2010","journal-title":"Drugs"},{"issue":"suppl 2","key":"10.1016\/bs.pmbts.2019.02.003_bb0300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/1158581-S0-000000000-00000","article-title":"Bemiparin: pharmacological profile","volume":"70","author":"Sanchez-Ferrer","year":"2010","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0305","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1586\/erc.10.35","article-title":"New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin","volume":"8","author":"Martinez-Gonzalez","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2\u20133","key":"10.1016\/bs.pmbts.2019.02.003_bb0310","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ejphar.2008.11.042","article-title":"Bemiparin improves the total antioxidant status in plasma","volume":"602","author":"Garcia-de-la-Asuncion","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.003_bb0315","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14779072.6.6.793","article-title":"Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism","volume":"6","author":"Martinez-Gonzalez","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0320","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1586\/14737167.6.3.249","article-title":"Cost-effectiveness of bemiparin in the prevention and treatment of venous thromboembolism","volume":"6","author":"Gomez-Outes","year":"2006","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0325","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.vph.2014.03.001","article-title":"Bemiparin, an effective and safe low molecular weight heparin: a review","volume":"62","author":"Ciccone","year":"2014","journal-title":"Vasc Pharmacol"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0330","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/ndt\/gft508","article-title":"Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin","volume":"29","author":"Pauwels","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0335","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MAT.0b013e31824c38c8","article-title":"Tinzaparin is safe and effective in the management of hemodialysis catheter thrombosis","volume":"58","author":"Quinlan","year":"2012","journal-title":"ASAIO J"},{"issue":"13","key":"10.1016\/bs.pmbts.2019.02.003_bb0340","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2165\/00003495-200464130-00006","article-title":"Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease","volume":"64","author":"Cheer","year":"2004","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.003_bb0345","first-page":"833","article-title":"Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin","volume":"90","author":"Maugeri","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0350","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11739-010-0479-1","article-title":"Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study","volume":"6","author":"Angeloni","year":"2011","journal-title":"Intern Emerg Med"},{"key":"10.1016\/bs.pmbts.2019.02.003_bb0355","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2147\/VHRM.S3430","article-title":"Update on the clinical use of the low-molecular-weight heparin, parnaparin","volume":"5","author":"Camporese","year":"2009","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0360","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2147\/VHRM.S3253","article-title":"Clinical use of parnaparin in major and minor orthopedic surgery: a review","volume":"4","author":"Bugamelli","year":"2008","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.003_bb0365","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1160\/TH06-12-0680","article-title":"Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood","volume":"97","author":"Maugeri","year":"2007","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.003_bb0370","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2165\/00003495-199447040-00007","article-title":"Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders","volume":"47","author":"Frampton","year":"1994","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.02.003_bb0375","doi-asserted-by":"crossref","first-page":"853","DOI":"10.7326\/0003-4819-132-11-200006060-00002","article-title":"Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial","volume":"132","author":"Heit","year":"2000","journal-title":"Ann Intern Med"},{"issue":"21","key":"10.1016\/bs.pmbts.2019.02.003_bb0380","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1001\/archinte.158.21.2325","article-title":"Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin","volume":"158","author":"Goldhaber","year":"1998","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.02.003_bb0385","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0390","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1538-7836.2012.04701.x","article-title":"Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE","volume":"10","author":"Lassen","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0395","first-page":"95","article-title":"Pharmacological and clinical differences between low-molecular-weight heparins: Implications for prescribing practice and therapeutic interchange","volume":"35","author":"Merli","year":"2010","journal-title":"P T"},{"issue":"20 suppl","key":"10.1016\/bs.pmbts.2019.02.003_bb0400","first-page":"S1026","article-title":"Overview of enoxaparin in the treatment of deep vein thrombosis","volume":"6","author":"Deitcher","year":"2000","journal-title":"Am J Manag Care"},{"issue":"15","key":"10.1016\/bs.pmbts.2019.02.003_bb0405","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.2010.31.9293","article-title":"Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer","volume":"29","author":"van Doormaal","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0410","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/asheducation-2018.1.399","article-title":"Management of thrombosis in children and neonates: practical use of anticoagulants in children","volume":"2018","author":"Monagle","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.003_bb0415","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2184.2012.00847.x","article-title":"The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines","volume":"45","author":"Carmazzi","year":"2012","journal-title":"Cell Prolif"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0420","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/ki.2013.163","article-title":"Use of enoxaparin in end-stage renal disease","volume":"84","author":"Lai","year":"2013","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/bs.pmbts.2019.02.003_bb0425","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nrcardio.2013.131","article-title":"Anticoagulation therapy: enoxaparin dosing for VTE during pregnancy","volume":"10","author":"Roberts","year":"2013","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.003_bb0430","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2013.09.026","article-title":"Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study","volume":"132","author":"Lecumberri","year":"2013","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0435","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00404-011-2055-y","article-title":"Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipid antibody syndrome","volume":"285","author":"Alalaf","year":"2012","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0440","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11845-013-0998-7","article-title":"Tinzaparin safety and efficacy in pregnancy","volume":"183","author":"Khalifeh","year":"2014","journal-title":"Ir J Med Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0445","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cyto.2012.06.008","article-title":"Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-kappaB activation on endothelial cell","volume":"60","author":"Li","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/bs.pmbts.2019.02.003_bb0450","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.carbpol.2016.12.037","article-title":"Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: a review","volume":"160","author":"Yan","year":"2017","journal-title":"Carbohydr Polym"},{"key":"10.1016\/bs.pmbts.2019.02.003_bb0455","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1877-1173(10)93020-2","article-title":"Glycosaminoglycans and activated contact system in cancer patient plasmas","volume":"93","author":"Pan","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"suppl 2","key":"10.1016\/bs.pmbts.2019.02.003_bb0460","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S0049-3848(14)50023-0","article-title":"Heparins and cancer survival: where do we stand?","volume":"133","author":"Noble","year":"2014","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/bs.pmbts.2019.02.003_bb0465","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.bbadis.2011.09.007","article-title":"Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-kappaB","volume":"1812","author":"Ettelaie","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.003_bb0470","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.thromres.2012.09.010","article-title":"Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study","volume":"130","author":"Elit","year":"2012","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.003_bb0475","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01220-2018","article-title":"Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial","volume":"52","author":"Meyer","year":"2018","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.02.003_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207387","article-title":"Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: a sub-study of RASTEN\u2014a randomized trial with low molecular weight heparin","volume":"13","author":"Gezelius","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0485","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/07853890.2015.1004361","article-title":"Low-molecular-weight heparins and cancer: focus on antitumoral effect","volume":"47","author":"Franchini","year":"2015","journal-title":"Ann Med"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2019.02.003_bb0490","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S0049-3848(12)70029-4","article-title":"Low-molecular-weight heparin and survival in lung cancer","volume":"129","author":"Noble","year":"2012","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0495","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejim.2013.01.006","article-title":"The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis","volume":"24","author":"Che","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.02.003_bb0500","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1440-1797.2008.01012.x","article-title":"Ability of low-molecular-weight heparin to alleviate proteinuria by inhibiting respiratory syncytial virus infection","volume":"13","author":"Guo","year":"2008","journal-title":"Nephrology (Carlton)"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.02.003_bb0505","first-page":"408","article-title":"Indigenous and imported low molecular weight heparin in the treatment of chronic hepatitis B and cirrhosis with hepatitis B virus: a prospective randomized controlled clinical study","volume":"19","author":"Huang","year":"2007","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue"},{"issue":"12","key":"10.1016\/bs.pmbts.2019.02.003_bb0510","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3390\/md10122795","article-title":"The antiviral activities and mechanisms of marine polysaccharides: an overview","volume":"10","author":"Wang","year":"2012","journal-title":"Mar Drugs"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0515","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/BF02592355","article-title":"Inhibition of HIV-1 infectivity by low molecular weight heparin. Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS","volume":"26","author":"Howell","year":"1996","journal-title":"Int J Clin Lab Res"},{"issue":"21","key":"10.1016\/bs.pmbts.2019.02.003_bb0520","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1021\/bi800205t","article-title":"Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1","volume":"47","author":"Copeland","year":"2008","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0525","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0741-5214(98)70060-6","article-title":"Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis","volume":"28","author":"Downing","year":"1998","journal-title":"J Vasc Surg"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0530","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.05959.x","article-title":"Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes","volume":"133","author":"Hochart","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0535","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s10753-014-9812-6","article-title":"Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats","volume":"37","author":"Luan","year":"2014","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0540","first-page":"24","article-title":"Low molecular weight heparin mediated regulation of nitric oxide synthase during burn wound healing","volume":"24","author":"Lakshmi","year":"2011","journal-title":"Ann Burns Fire Disasters"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.003_bb0545","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1056-8727(02)00250-7","article-title":"Diabetic rats treated by low molecular weight heparin OP 2123\/parnaparin: morphological changes in the kidney and heart","volume":"18","author":"Artico","year":"2004","journal-title":"J Diabetes Complicat"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.003_bb0550","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1439-0264.2002.00373.x","article-title":"Morphological changes in the sciatic nerve of diabetic rats treated with low molecular weight heparin OP 2123\/parnaparin","volume":"31","author":"Artico","year":"2002","journal-title":"Anat Histol Embryol"},{"issue":"21","key":"10.1016\/bs.pmbts.2019.02.003_bb0555","first-page":"1327","article-title":"The protective effect of low molecular weight heparin on early nephropathy in diabetic rats","volume":"81","author":"Guo","year":"2001","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.003_bb0560","first-page":"382","article-title":"Effects of low molecular weight heparin on vascular endothelial growth factor expression of early diabetic nephropathy","volume":"37","author":"Gan","year":"2005","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0565","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1172\/JCI32169","article-title":"Cellular and molecular basis of wound healing in diabetes","volume":"117","author":"Brem","year":"2007","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.02.003_bb0570","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1464-5491.2008.02527.x","article-title":"Treatment of chronic diabetic foot ulcers with bemiparin: a randomized, triple-blind, placebo-controlled, clinical trial","volume":"25","author":"Rullan","year":"2008","journal-title":"Diabet Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.003_bb0575","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/biolre\/ioy127","article-title":"Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia","volume":"99","author":"Wat","year":"2018","journal-title":"Biol Reprod"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.003_bb0580","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1039\/b819896a","article-title":"Lessons learned from the contamination of heparin","volume":"26","author":"Liu","year":"2009","journal-title":"Nat Prod Rep"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.003_bb0585","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrd966","article-title":"Antithrombotic drug market","volume":"2","author":"Collins","year":"2003","journal-title":"Nat Rev Drug Discov"}],"container-title":["Progress in Molecular Biology and Translational Science","Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T09:30:30Z","timestamp":1663147830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117319300249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177402"],"references-count":116,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2019.02.003","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}